1.43Open1.15Pre Close52 Volume619 Open Interest240.00Strike Price5.62KTurnover42.24%IV5.91%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type-0.1893Delta0.0157Gamma137.25Leverage Ratio-0.2444Theta-0.0119Rho-25.98Eff Leverage0.1103Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet